B.Riley Downgrades X4 Pharmaceuticals (XFOR) to Neutral, 'longer-term data indicate that mavorixafor monotherapy is insufficient to sustain ANC responses in CN patients'
Tweet Send to a Friend
(Updated - December 12, 2023 6:54 AM EST)
B.Riley analyst Kalpit Patel downgraded X4 Pharmaceuticals (NASDAQ: XFOR) from Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
B.Riley analyst Kalpit Patel downgraded X4 Pharmaceuticals (NASDAQ: XFOR) from Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
